A.; 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy.
A.; Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria.
E.; Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
F.; Working formulation for the standardization of definitions of infections in patients using ventricular assist devices.
M.M.; The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005–2011).
S.M.; Report from a consensus conference on antibody-mediated rejection in heart transplantation.
L.; A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients.
S.; HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).
D.M.; Cirrhotic cardiomyopathy.
J.D.; Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.
P.J.; Exercise training in heart failure: practical guidance.
G.J.; The role of exercise training in heart failure.
M.R.; Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists.
W.J.; Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.
T.C.; Medical and surgical treatment of acute right ventricular failure.
T.D.; Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications.
T.; Pregnancy in patients with pre-existing cardiomyopathies.
C.M.; Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.
G.M.; Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications.
A.F.; Effect of nesiritide in patients with acute decompensated heart failure.
R.C.; Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
D.A.; Diuretic strategies in patients with acute decompensated heart failure.
H.; Eplerenone in patients with systolic heart failure and mild symptoms.
I.Z.; Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
M.; Cardiac-resynchronization therapy for mild-to-moderate heart failure.
M.; Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
T.E.; Primary results from the SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy.
T.M.; Heart disease and stroke statistics—2010 update: a report from the American Heart Association.
R.S.; Validation of the Health ABC Heart Failure Model for incident heart failure risk prediction: the Cardiovascular Health Study.
T.N.; Predictors of incident heart failure in a large insured population: a one million person-year follow-up study.
E.; Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community.
A.; Regional left ventricular myocardial dysfunction as a predictor of incident cardiovascular events MESA (Multi-Ethnic Study of Atherosclerosis).
S.; Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort.
P.; Occupational, commuting, and leisure-time physical activity in relation to heart failure among Finnish men and women.
A.; The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.
L.W., van Pol
W.E.; Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?) study.
V., de Lemos
J.A.; Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities study.
C.R., de Lemos
R.H.; Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.
M.G.; Multimarker approach for the prediction of heart failure incidence in the community.
P.; Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.
A.; Iron deficiency: an ominous sign in patients with systolic chronic heart failure.
O., dos Remedios
D.M.; Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure.
C.; Inherited cardiomyopathies.
P.; Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure.
W.; National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities.
M.; Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
B.M.; Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
R.C.; Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial.
M.; Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
M.D.; PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
U.; Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.
G.; Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.
H.; Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure).
R.M.; Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?.
J.C.; Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
M.A.; Coronary-artery bypass surgery in patients with left ventricular dysfunction.
K.L.; Myocardial viability and survival in ischemic left ventricular dysfunction.
J.A.; Assessment of myocardial fibrosis with cardiovascular magnetic resonance.
A.; Long-term results after a telephone intervention in chronic heart failure: DIAL (Randomized Trial of Phone Intervention in Chronic Heart Failure) follow-up.
J.P.; Telemonitoring in patients with heart failure.
M.; Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study.
T.D.; Chronic ambulatory intracardiac pressures and future heart failure events.
R.C.; Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee.
D.; The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy.
Y.; Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
A.Y.; Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation.
R.L.; Impact of renal function before mechanical circulatory support on posttransplant renal outcomes.
J.K.; Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience.
L.H.; A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial.
U.; Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: a prospective, comparative study.
A.J.; Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).
C.; Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.
U.P.; Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.
E.S.; Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation.
T.J.; The development of aortic insufficiency in left ventricular assist device-supported patients.
S.W.; Aortic valve procedures at the time of ventricular assist device placement.
T.; Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices.
M.J.; Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification.
S.; Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience.
M.; Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial.
M.; Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study.
S.S.; Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support.
P.; The percutaneous ventricular assist device in severe refractory cardiogenic shock.
M.K.; Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
A.A., de Leeuw
P.W.; Novel procedure- and device-based strategies in the management of systemic hypertension.
M.; Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.
D.; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
K.; Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome.
K., Ng Kam Chuen
R.J.; Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function.
J.; Non-evidence-based ICD implantations in the United States.
M.R.; Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry.
J.P.; Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction.
M.A.; An entirely subcutaneous implantable cardioverter-defibrillator.
A.J.; Cardiac resynchronization therapy in patients with minimal heart failure a systematic review and meta-analysis.
N.; Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.
E.; Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial.
M.; Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy.
A.J.; Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
G.J.; Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients.
V., van Bommel
M.; Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy.
D.T.; Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) trial.
M.; Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure.
M.M.; Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.
B.R., Brunner-La Rocca
D.M.; Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction.
B.; Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction.
D.L.; Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF).
P.H.; A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility.
W.C.; Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.
B.; Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006.
G.C.; Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries.
P.C.; Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department.
A.B.; Associations between outpatient heart failure process-of-care measures and mortality.
C.W.; Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
A.K.; The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure.
D.E.; ACCF/AHA/HFSA 2011 survey results: current staffing profile of heart failure programs, including programs that perform heart transplant and mechanical circulatory support device implantation: a report of the ACCF Heart Failure and Transplant Committee, AHA Heart Failure and Transplantation Committee, and Heart Failure Society of America.
A.B.; Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).